Morbidity and mortality of patients with diabetic neuropathy treated with pathogenetically oriented alpha-lipoic acid versus symptomatic pharmacotherapies – A nationwide database analysis from Hungary
Authors' conclusion
This retrospective database analysis revealed a lower occurrence of cardio- and cerebrovascular morbidity, cancer events and all-cause mortality in patients with diabetic neuropathy treated with pathogenetically oriented ALA vs symptomatic pharmacotherapies. This hypothesis-generating result requires further investigations.
Study context
- Population
- Patients treated for diabetic neuropathy in Hungary, 2009–2019propensity score matched
- Exposure
- Pathogenetically oriented alpha-lipoic acid (ALA) vs symptomatic pharmacotherapies
- Outcome
- Clinical outcomes
Methodological detailsnationwide database analysis, propensity score matched, sensitivity analyses
- Nationwide database analysis
- Propensity score matched
- Sensitivity analyses
Main finding
As reported in the abstract
Each group vs symptomatic pharmacotherapiesEstimate (95% CI)P value
ALA
HR, acute MI 0.73(0.60–0.89)
P = 0.0016ALA
HR, stroke 0.71(0.62–0.82)
P < 0.0001ALA
HR, hospitalization for HF 0.72(0.66–0.78)
P < 0.0001ALA
HR, cancer events 0.83(0.76–0.92)
P = 0.0002ALA
HR, all-cause mortality 0.55(0.49–0.61)
P < 0.0001ALA
HR, lower limb amputation 1.05(0.89–1.25)
P = 0.5455Observational data: associations, not effects.
Original publication
Morbidity and mortality of patients with diabetic neuropathy treated with pathogenetically oriented alpha-lipoic acid versus symptomatic pharmacotherapies – A nationwide database analysis from Hungary. Diabetes Res Clin Pract. Published 29 May 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →